143 urn:lsid:arphahub.com:pub:892805cc-c5d0-571f-8841-3ba335035073 Review of Clinical Pharmacology and Pharmacokinetics – International Edition RCPP 1011-6583 2945-1922 PHARMAKON-Press 10.61873/HHPT2430 34818 Research Article Evaluation of serum cystatin C levels in multiple myeloma: diagnostic significance and clinical implications Mousa Mazin J. 1 Al-Hindy Hayder Abdul-Amir 1 Al-Mumin Amir Saheb 2 College of Pharmacy, University of Babylon, Hillah, Iraq College of Pharmacy, University of Babylon Hillah Iraq Hammurabi Medical College, University of Babylon, Hillah, Iraq Hammurabi Medical College, University of Babylon Hillah Iraq

Academic editor:

2024 05 05 2024 38 s2 145 148 188CD678-3F1E-51FC-92E4-2A47D1DF17E9 Mazin J. Mousa, Hayder Abdul-Amir Al-Hindy, Amir Saheb Al-Mumin This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Cystatin C (CysC) levels in patients with multiple myeloma (MM) have been linked to tumour load and outcomes’ prediction. This study aimed at assessing the diagnostic utility of CysC in distinguishing MM patients from controls and advanced stages of MM. In total, 98 MM patients and 57 healthy controls participated in this cross-sectional case-control study. Demographic, clinical, and biochemical data were assessed. The study groups exhibited significantly diverse measures of urea, creatinine, CysC, β 2 -microglobulin, and lactate dehydrogenase activity. β 2 -Microglobulin was found to be a reliable predictor for both the MM staging and its diagnosis, but CysC was found to only possess a partial capacity of predicting advanced MM stages. Our results highlight the significance of taking into account many biomarkers in the therapy of MM, so as to achieve effective clinical evaluation. More research is required in order to clarify the CysC implication in the prognosis and management of MM.